Skip Navigation

Cardiovascular Research 2005 66(1):141-149; doi:10.1016/j.cardiores.2004.12.024
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Viñals, M.
Right arrow Articles by Laguna, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Viñals, M.
Right arrow Articles by Laguna, J. C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 2005, European Society of Cardiology

Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages

Marisa Viñals*, Ignacio Bermúdez, Gemma Llaverias, Marta Alegret, Rosa Maria Sanchez, Manuel Vázquez-Carrera and Juan Carlos Laguna

Unitat de Farmacologia, Facultat de Farmacia, Universitat de Barcelona, Nucli Universitari de Pedralbes, E-08028 Barcelona, Spain

* Corresponding author. Present address: Centre de Génétique Moléculaire, Centre National de la Recherche Scientifique, 91198 Gif-sur-Yvette Cedex France. Tel.: +33 1 69 82 3168; fax: +33 1 69 82 43 86. Email address: mvinals{at}lloguerspous.com

Objective: CD36 is a receptor, whose expression increases during the differentiation of monocytes to macrophages, playing a key role in the phagocytosis of apoptotic cells and in the formation of foam cells during atherosclerosis. Recently, it has been described that ligands of PPAR{gamma} induce CD36 expression and inhibit cyclooxygenase expression in macrophages. Our aim was to study whether the reduction of endogenous prostaglandin production could modify CD36 expression in macrophages and to outline the potential mechanism.

Methods and results: CD36 expression was measured by flow cytometry in THP-1 cells differentiated to macrophages that had been incubated with aspirin (ASA) alone or in combination with PGE2, sulprostone (EP1/EP3 agonist), butaprost (EP2 agonist,) and PGE1 alcohol (EP2/EP4 agonist). Aspirin induced CD36 expression. Only PGE2 and PGE1 alcohol completely abolished CD36 induction by aspirin, whereas butaprost strongly reduced it. BADGE (a PPAR{gamma} antagonist) or diclofenac (a PPAR{gamma} antagonist and a cyclooxygenase inhibitor) in aspirin-incubated cells did not reduce CD36 induction. On the other hand, aspirin also induced the expression of SR-BI and ABCA1, an HDL receptor and an HDL formation-related protein, respectively.

Conclusions: Aspirin produces an increase of CD36 expression in THP-1 macrophages by a PGE2-dependent mechanism. The PGE2 receptors implicated in CD36 modulation by ASA are the EP2/EP4 subtypes. Further, we provide evidence of SR-BI and ABCA1 induction by aspirin treatment.

KEYWORDS Acetylsalicylic acid; Aspirin; CD36; SR-BI; ABCA-1; Macrophages; PPAR; Prostaglandins

Time for primary review 26 days


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
S. Collot-Teixeira, J. Martin, C. McDermott-Roe, R. Poston, and J. L. McGregor
CD36 and macrophages in atherosclerosis
Cardiovasc Res, August 1, 2007; 75(3): 468 - 477.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.